Radar · Life Sciences in Canada
Best Life Sciences Companies in Canada
The 1567 best Life Sciences companies in Canada in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Bausch Health.
By Rohit KhannaTrends & Stories
1567companies tracked
$36.2Bdisclosed funding
0unicorns
582have raised
Canada's Life Sciences sector has 1,567 tracked companies and $36.2B in disclosed funding behind them, and if you want to know which ones have actually raised, this directory ranks them by equity funding and recent momentum. No unicorns yet, but the capital is moving. ProMIS Neurosciences leads the pack at $247M, Lungpacer sits at $111M, and Spineology and Congruence Therapeutics have pulled $67M and $65M respectively. That spread tells you something: this isn't a winner-takes-all market, it's a wide field with real money distributed across therapeutic niches. BDC, the Ontario Brain Institute, and MaRS Discovery District are the repeat backers you'll see across the cap table.
Hot themes right now are stem cell banking, cell-based therapies, diagnostic biotechnology, and gene delivery systems, which tracks with the global life sciences growth trajectory running at roughly 10.2% CAGR. Median app install growth across health and life sciences platforms is up 43% year-over-year, and deals like SAI Life Sciences' IPO push and Asahi Songwon's API acquisition show global players consolidating fast. I'd watch the diagnostics and gene delivery cohort here particularly closely. The funding signals are early but the direction isn't ambiguous.
Sources & further reading
- Pharmaceutical Majors Build Positions in Monoclonal Antibodies
- AI in Drug Discovery Market to Reach USD 160.49 Billion, Rising at a 23.22% CAGR
- Morgan Stanley Ups the Ante on These 2 Life Science Tool Stocks
FLIAR INTELLIGENCE · LIFE SCIENCES × CANADA
Our analysis of 50 Life Sciences companies
$27.5b in tracked funding; 76% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
50companies analysed
76%cloud-native stacks
2025funding peak (by rounds)
2013median founding year
45median Fliar Index™
434kcombined LinkedIn audience
46%of audience held by top 3
4companies hiring publicly (12 mo)
Ranked: Best Life Sciences companies in Canada
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Market signals (1y) | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Bausch Health Developer of therapeutics for the treatment of multiple diseases 67Market top 23%Funding top 27%Product top 29%Innovation top 34% All 10 signals ▾Markettop 23% Fundingtop 27% Producttop 29% Innovationtop 34% Newstop 37% Talenttop 39% Globaltop 41% Techtop 45% Fin. healthtop 49% Growthbottom 36% Market: 808 employees (top 2% of Life Sciences) · Revenue ~$8.7B Funding: Raised $25.7B across 6 rounds · 6 rounds over 11 yrs (0.5/yr) rank vs industry peers · Fliar Intelligence Index 67/100 | $25.7B | 87 mo ago | 808 | Joseph Papa CEO | BootstrapAzureMicrosoft Application Insights+15 | 25 signals ▼39% Earnings · M&A · Leadership | — | 1 internship |
| 2 | ProMIS Neurosciences Antibody therapeutics and diagnostics for neurodegenerative diseases 37Funding top 10%Patents top 38%Moat top 38%Talent top 38% All 9 signals ▾Fundingtop 10% Patentstop 38% Moattop 38% Talenttop 38% Newstop 42% Innovationtop 47% Globalbottom 48% Techbottom 34% Marketbottom 24% Funding: Raised $247M across 37 rounds · 37 rounds over 20 yrs (1.9/yr) Patents: 78 patents matched (strict assignee match) · 29 filings since 2022 vs 39 in 2017-21 rank vs industry peers · Fliar Intelligence Index 37/100 | $247M | 4 mo ago | 7 | Neil Cashman Co-Founder | BootstrapApache HTTP ServerjQuery+10 | — | 78 patents Therapeutic antibodies targeting misfolded neurodegenerative proteins (TDP-43, α‑synuclein, Aβ, SOD1). | — |
| 3 | Cybin Provider of psychedelic therapeutics for psychiatric disorders 55Funding top 15%Tech top 42%Talent top 45%Moat top 48% All 6 signals ▾Fundingtop 15% Techtop 42% Talenttop 45% Moattop 48% Marketbottom 47% Globalbottom 37% Funding: Raised $230M across 6 rounds · 6 rounds over 6 yrs (1.0/yr) Tech: 34 technologies across 4/8 capability areas · Cloud: Cloudflare rank vs industry peers · Fliar Intelligence Index 55/100 | $230M | 11 mo ago | 50 | Aaron Bartlone COO | BugHerdQ4MediaElement.js+17 | — | — | — |
| 4 | Kardium Developer of ablation device for atrial fibrillation 78Funding top 20%Patents top 25%Product top 25%Moat top 26% All 11 signals ▾Fundingtop 20% Patentstop 25% Producttop 25% Moattop 26% Innovationtop 27% Talenttop 28% Growthtop 35% Markettop 42% Techtop 42% Globalbottom 44% Newsbottom 20% Funding: Raised $221M across 5 rounds · 5 rounds over 16 yrs (0.3/yr) Patents: 446 patents matched (strict assignee match) · 131 filings since 2022 vs 180 in 2017-21 rank vs industry peers · Fliar Intelligence Index 78/100 | $221M | 11 mo ago | 230 | Sam Lichtenstein Co-Founder | WordPress Block EditorWordPressMySQL+20 | — | 446 patents Cardiac electrophysiology: catheter navigation, high‑density mapping, and pulsed‑field ablation systems | 1 award |
| 5 | Lungpacer Developer of a neurostimulation-based pacer for diaphragm strength 50Funding top 23%Innovation top 27%Moat top 31%Product top 35% All 8 signals ▾Fundingtop 23% Innovationtop 27% Moattop 31% Producttop 35% Techtop 43% Talentbottom 49% Globalbottom 40% Marketbottom 28% Funding: Raised $111M across 8 rounds · 8 rounds over 13 yrs (0.6/yr) Innovation: 3 product lines · Deep-tech classification: Tech Hardware rank vs industry peers · Fliar Intelligence Index 50/100 | $111M | 1 mo ago | — | Doug Evans President & CEO | WordPressApple iCloud MailMySQL+18 | — | — | 3 launchs |
| 6 | ABK Biomedical Developer of imageable embolic medical devices targeting benign and malignant hypervascular tumors 48Funding top 24%Moat top 32%Growth top 35%Patents top 36% All 10 signals ▾Fundingtop 24% Moattop 32% Growthtop 35% Patentstop 36% Talenttop 38% Innovationtop 39% Techbottom 48% Newsbottom 42% Globalbottom 42% Marketbottom 20% Funding: Raised $79.3M across 7 rounds · 7 rounds over 14 yrs (0.5/yr) Moat: Editorial + unicorn rating 7/10 · IP moat: 43 patents rank vs industry peers · Fliar Intelligence Index 48/100 | $79M | 8 mo ago | 1 | Sharon Kehoe Co-Founder | WordPressMySQLPHP+19 | — | 43 patents Medical drug delivery devices and radiopaque microparticle formulations for imaging and therapy | — |
| 7 | Synaptive Medical Planning and imaging solutions for neurosurgery 74Patents top 20%Funding top 23%Product top 25%Moat top 26% All 11 signals ▾Patentstop 20% Fundingtop 23% Producttop 25% Moattop 26% Innovationtop 31% Growthtop 35% Talenttop 38% Techtop 41% Markettop 43% Globaltop 45% Newsbottom 21% Patents: 730 patents matched (strict assignee match) · 264 filings since 2022 vs 378 in 2017-21 Funding: Raised $76.8M across 12 rounds · 12 rounds over 12 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 74/100 | $77M | 11 mo ago | 200 | Cameron Piron Co-Founder | WordPressApple iCloud MailMySQL+19 | — | 730 patents Patents concentrated in health & consumer products | — |
| 8 | Spineology Developer of minimally invasive spinal surgery devices 57Funding top 25%Tech top 32%Moat top 39%Growth top 45% All 8 signals ▾Fundingtop 25% Techtop 32% Moattop 39% Growthtop 45% Marketbottom 49% Talentbottom 49% Globalbottom 37% Newsbottom 18% Funding: Raised $67.0M across 12 rounds · 12 rounds over 24 yrs (0.5/yr) Tech: 33 technologies across 4/8 capability areas · Cloud: Cloudflare rank vs industry peers · Fliar Intelligence Index 57/100 | $67M | 7 mo ago | 94 | Brian Snider Chief Executive Officer | WordPressMySQLPHP+24 | — | — | 2 launchs |
| 9 | Congruence Therapeutics Developer of therapeutics for the treatment of rare diseases 50AI top 20%Funding top 24%Moat top 31%Talent top 38% All 8 signals ▾AItop 20% Fundingtop 24% Moattop 31% Talenttop 38% Marketbottom 38% Globalbottom 38% Techbottom 31% Newsbottom 22% AI: Classified as an AI company Funding: Raised $65.0M across 4 rounds · 4 rounds over 4 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 50/100 | $65M | 2 mo ago | 33 | Michael Goldsmith Co-Founder | WordPressMySQLPHP+18 | — | — | — |
| 10 | Nomic Provider of next-generation proteomics platform for drug discovery and protein analysis 60Funding top 27%Growth top 28%Talent top 28%Moat top 39% All 8 signals ▾Fundingtop 27% Growthtop 28% Talenttop 28% Moattop 39% Techtop 46% Globalbottom 43% Marketbottom 39% Newsbottom 18% Funding: Raised $63.0M across 2 rounds · 2 rounds over 6 yrs (0.3/yr) Growth: Web rank 50,000,000 → 10,000,000 YoY · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 60/100 | $63M | 21 mo ago | 43 | Jeff Munzar Co-Founder & CTO | WebflowSentryWistia+22 | — | — | 1 partnership |
| 11 | enGene Developer of oral non-viral gene therapy platform 50Patents top 28%Moat top 29%Funding top 30%Innovation top 38% All 9 signals ▾Patentstop 28% Moattop 29% Fundingtop 30% Innovationtop 38% Newstop 46% Growthtop 48% Marketbottom 46% Techbottom 45% Globalbottom 44% Patents: 174 patents matched (strict assignee match) · 40 filings since 2022 vs 69 in 2017-21 Moat: Editorial + unicorn rating 6/10 · IP moat: 174 patents rank vs industry peers · Fliar Intelligence Index 50/100 | $54M | 19 mo ago | 57 | — | WordPressApple iCloud MailMySQL+28 | 12 signals ▼33% Earnings · Leadership · Announcements | 174 patents Chitosan nanoparticle gene delivery platforms for cancer immunotherapy and localized gene expression | 1 internship · 2 awards |
| 12 | Morphocell Technologies Developer of an engineered liver for the treatment of liver diseases 45Talent top 28%Funding top 31%Growth top 35%Moat top 42% All 7 signals ▾Talenttop 28% Fundingtop 31% Growthtop 35% Moattop 42% Techtop 49% Globalbottom 36% Marketbottom 25% Talent: Analyst team rating 4/5 Funding: Raised $50.0M across 2 rounds · 2 rounds over 5 yrs (0.4/yr) rank vs industry peers · Fliar Intelligence Index 45/100 | $50M | 6 mo ago | 9 | — | WixSentryEnvoy+12 | — | — | 1 expansion · 1 award |
| 13 | Oncolytics Biotech Develops oncolytic viruses for use as cancer therapeutics 48Patents top 29%Product top 30%Funding top 31%News top 33% All 11 signals ▾Patentstop 29% Producttop 30% Fundingtop 31% Newstop 33% Innovationtop 41% Moattop 41% Growthtop 47% Techtop 47% Talentbottom 49% Marketbottom 38% Globalbottom 37% Patents: 450 patents matched (strict assignee match) · 6 filings since 2022 vs 40 in 2017-21 Product: 1 distinct product line · Company stage: Public rank vs industry peers · Fliar Intelligence Index 48/100 | $48M | 14 mo ago | 29 | Matt Coffey President and Chief Executive Officer | WordPressMySQLPHP+18 | 16 signals ▼43% Earnings · Acquisition · Regulatory | 450 patents Oncolytic virotherapy and viral formulation for cancer immunotherapy | — |
| 14 | Feldan Developing delivery system of proteins inside cells directly 29Funding top 33%Moat top 38%Tech bottom 46%Market bottom 38% All 5 signals ▾Fundingtop 33% Moattop 38% Techbottom 46% Marketbottom 38% Globalbottom 37% Funding: Raised $40.4M across 6 rounds · 6 rounds over 11 yrs (0.5/yr) Moat: Editorial + unicorn rating 4/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 29/100 | $40M | 14 mo ago | 36 | — | HubSpot CMS HubSplideIsotope+17 | — | — | — |
| 15 | Flosonics Medical Developer of non-invasive hemodynamic monitoring devices 48Funding top 29%Moat top 32%Product top 35%Patents top 39% All 9 signals ▾Fundingtop 29% Moattop 32% Producttop 35% Patentstop 39% Innovationtop 42% Techtop 44% Globalbottom 43% Marketbottom 39% Newsbottom 22% Funding: Raised $39.0M across 4 rounds · 4 rounds over 8 yrs (0.5/yr) Moat: Editorial + unicorn rating 7/10 · IP moat: 22 patents rank vs industry peers · Fliar Intelligence Index 48/100 | $39M | 15 mo ago | 38 | — | WordPressApple iCloud MailGoogle Workspace+37 | — | 22 patents Wearable ultrasound flow sensing patches and dynamic fluid control systems for medical applications | 2 job openings · 2 awards |
| 16 | Helix BioPharma Developer of therapies for the treatment and prevention of cancer 35Product top 14%Moat top 28%Funding top 34%Patents top 38% All 11 signals ▾Producttop 14% Moattop 28% Fundingtop 34% Patentstop 38% Innovationtop 44% Techtop 47% Talentbottom 49% Growthbottom 47% Newsbottom 43% Globalbottom 43% Marketbottom 23% Product: 5 distinct product lines · Company stage: Public Moat: Editorial + unicorn rating 5/10 · IP moat: 110 patents rank vs industry peers · Fliar Intelligence Index 35/100 | $36M | 9 mo ago | 7 | Jacek Antas Ceo & Chairman Of The Executive Board | WordPressMySQLPHP+23 | 3 signals ▼83% Regulatory · Announcements · Earnings | 110 patents Engineered immune‑cell and antibody‑enzyme therapeutics for tumor microenvironment modulation | — |
| 17 | Sernova Regenerative medicine to deliver proteins and hormones for disease treatment 37Funding top 24%Talent top 28%Moat top 38%Patents top 41% All 10 signals ▾Fundingtop 24% Talenttop 28% Moattop 38% Patentstop 41% Newstop 46% Innovationbottom 45% Globalbottom 43% Growthbottom 40% Marketbottom 37% Techbottom 36% Funding: Raised $32.5M across 28 rounds · 28 rounds over 25 yrs (1.1/yr) Talent: Analyst team rating 4/5 rank vs industry peers · Fliar Intelligence Index 37/100 | $32M | 7 mo ago | 21 | — | WordPressMySQLPHP+13 | 6 signals ▼57% Announcements | 66 patents Patents concentrated in health & consumer products | 1 launch |
| 18 | Exact Imaging Developer of micro-ultrasound based imaging device 45Funding top 28%Moat top 32%Growth top 35%Patents top 46% All 9 signals ▾Fundingtop 28% Moattop 32% Growthtop 35% Patentstop 46% Talentbottom 49% Innovationbottom 47% Techbottom 44% Globalbottom 42% Marketbottom 39% Funding: Raised $29.9M across 5 rounds · 5 rounds over 13 yrs (0.4/yr) Moat: Editorial + unicorn rating 7/10 · IP moat: 45 patents rank vs industry peers · Fliar Intelligence Index 45/100 | $30M | 4 mo ago | 32 | Randy Aucoin President & CEO | ExpressionEnginePHPSalesforce+19 | — | 45 patents High‑resolution ultrasound imaging and needle‑guidance systems for interventional diagnostics | — |
| 19 | Fresh Prep Online platform to buy recipe box with pre-prepped ingredients 64Tech top 25%Market top 32%Growth top 37%Talent top 38% All 10 signals ▾Techtop 25% Markettop 32% Growthtop 37% Talenttop 38% Fundingtop 39% Moattop 41% Patentsbottom 43% Innovationbottom 39% Globalbottom 37% Newsbottom 21% Tech: 51 technologies across 6/8 capability areas · Cloud: Cloudflare Market: 431 employees (top 3% of Life Sciences) · Top-500,000 web property rank vs industry peers · Fliar Intelligence Index 64/100 | $28M | 11 mo ago | 431 | Dhruv Sood Co-Founder & Co-CEO | ContentfulFacebook LoginGoogle Sign-in+28 | — | 5 patents Reusable insulated containers for meal kit delivery and food packaging | 1 award |
| 20 | Conavi A catheter-based ultrasound system for cardiac imaging 48Funding top 24%Growth top 38%News top 38%Partners top 40% All 9 signals ▾Fundingtop 24% Growthtop 38% Newstop 38% Partnerstop 40% Moattop 48% Talentbottom 49% Marketbottom 48% Techbottom 41% Globalbottom 29% Funding: Raised $27.7M across 5 rounds · 5 rounds over 7 yrs (0.7/yr) Growth: 2 acquisition/expansion moves in 24 mo · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 48/100 | $28M | 5 mo ago | 76 | Aman Thind Co-founder and Chief Technology Officer | YouTubeGoogle Cloudstyled-components+6 | 14 signals ▼18% Regulatory · Announcements · Earnings | — | 1 launch · 2 awards |
| 21 | A Better Life Pharma Developer of cannabinoid-based therapeutics for neurological disorders 24Growth top 35%Funding top 36%News top 39%Tech bottom 48% All 7 signals ▾Growthtop 35% Fundingtop 36% Newstop 39% Techbottom 48% Globalbottom 43% Talentbottom 41% Marketbottom 11% Growth: Fresh capital in last 24 mo Funding: Raised $25.7M across 14 rounds · 14 rounds over 6 yrs (2.3/yr) rank vs industry peers · Fliar Intelligence Index 24/100 | $26M | 13 mo ago | 4 | Ahmad Doroudian Founder & CEO | WordPress Block EditorElementorWordPress+27 | — | — | — |
| 22 | Zucara Therapeutics Developing a long-term therapeutic approach to prevent hypoglycemia in patients with diabetes 29Product top 35%Funding top 36%Innovation top 38%Moat top 39% All 8 signals ▾Producttop 35% Fundingtop 36% Innovationtop 38% Moattop 39% Talentbottom 49% Globalbottom 36% Techbottom 35% Marketbottom 27% Product: 3 distinct product lines · Company stage: Series B Funding: Raised $25.4M across 7 rounds · 7 rounds over 11 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 29/100 | $25M | 16 mo ago | 12 | Richard Liggins Co Founder & Chief Scientific Officer | WordPressMySQLPHP+13 | — | — | — |
| 23 | Puzzle Medical Devices Developer of a minimally invasive heart pump 57Patents top 24%Talent top 28%Innovation top 31%Moat top 31% All 9 signals ▾Patentstop 24% Talenttop 28% Innovationtop 31% Moattop 31% Growthtop 35% Fundingtop 37% Techbottom 48% Globalbottom 42% Marketbottom 35% Patents: 64 patents matched (strict assignee match) · 50 filings since 2022 vs 14 in 2017-21 Talent: 3 named leaders on record · 3 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 57/100 | $25M | 15 mo ago | 24 | Gabriel Georges Co-Founder | WixSentryApple iCloud Mail+13 | — | 64 patents Implantable modular fluid‑flow control and drug‑delivery pump systems for medical use | 3 job openings |
| 24 | MedX Health Developer of skin analysis and assessment systems 32Funding top 36%Moat top 38%Tech top 39%Growth bottom 47% All 9 signals ▾Fundingtop 36% Moattop 38% Techtop 39% Growthbottom 47% Patentsbottom 45% Innovationbottom 44% Globalbottom 38% Newsbottom 33% Marketbottom 28% Funding: Raised $21.3M across 21 rounds · 21 rounds over 10 yrs (2.1/yr) Moat: Editorial + unicorn rating 5/10 · IP moat: 15 patents rank vs industry peers · Fliar Intelligence Index 32/100 | $21M | 4 mo ago | 16 | — | Cart FunctionalitySquarespace CommerceSquarespace+24 | — | 15 patents Patents concentrated in health & consumer products | 3 launchs |
| 25 | Revive Therapeutics Developer of therapeutics to treat rare and infectious diseases 27Product top 24%Moat top 32%Funding top 36%Patents top 42% All 10 signals ▾Producttop 24% Moattop 32% Fundingtop 36% Patentstop 42% Innovationtop 44% Growthtop 48% Techbottom 48% Newsbottom 43% Globalbottom 31% Marketbottom 16% Product: 2 distinct product lines · Company stage: Public Moat: Editorial + unicorn rating 5/10 · IP moat: 24 patents rank vs industry peers · Fliar Intelligence Index 27/100 | $17M | 10 mo ago | 3 | — | WordPressMySQLPHP+16 | 3 signals ▼57% Funding | 24 patents Neuroprotective and anti‑infective therapeutics repurposing bucillamine and psilocybin | — |
| 26 | Zenith Epigenetics Developer of small molecule BET inhibitors for cancer and autoimmune disorders 21Moat top 28%Patents top 33%Innovation top 42%Funding top 50% All 9 signals ▾Moattop 28% Patentstop 33% Innovationtop 42% Fundingtop 50% Productbottom 47% Globalbottom 37% Marketbottom 28% Techbottom 28% Newsbottom 27% Moat: Editorial + unicorn rating 4/10 · IP moat: 187 patents Patents: 187 patents matched (strict assignee match) · 23 filings since 2022 vs 115 in 2017-21 rank vs industry peers · Fliar Intelligence Index 21/100 | $17M | 13 mo ago | 16 | — | PHPUbuntuBootstrap+7 | — | 187 patents Patents concentrated in health & consumer products | — |
| 27 | Appili Therapeutics Developer of drugs to treat infectious diseases 32Funding top 31%Product top 32%Tech top 40%Moat top 42% All 10 signals ▾Fundingtop 31% Producttop 32% Techtop 40% Moattop 42% Newstop 49% Patentstop 50% Globalbottom 48% Growthbottom 47% Innovationbottom 44% Marketbottom 27% Funding: Raised $15.5M across 18 rounds · 18 rounds over 10 yrs (1.8/yr) Product: 3 distinct product lines · Company stage: Acquired rank vs industry peers · Fliar Intelligence Index 32/100 | $16M | 6 mo ago | 9 | — | WordPressMySQLPHP+24 | 5 signals ▼71% Earnings · Funding | 15 patents Oral antimicrobial formulations and antifungal therapies targeting Candida auris infections | — |
| 28 | Future Fields Biomanufacturing unit for serum-free, bioactive growth factors, and other recombinant proteins 37Moat top 37%Funding top 39%Patents top 44%Tech top 49% All 9 signals ▾Moattop 37% Fundingtop 39% Patentstop 44% Techtop 49% Talentbottom 49% Innovationbottom 46% Marketbottom 42% Globalbottom 40% Newsbottom 18% Moat: Editorial + unicorn rating 7/10 · IP moat: 7 patents Funding: Raised $13.6M across 4 rounds · 4 rounds over 6 yrs (0.7/yr) rank vs industry peers · Fliar Intelligence Index 37/100 | $14M | 12 mo ago | 40 | Matt Anderson-Baron Chief Executive Officer | Shogun Page BuilderCart FunctionalityShopify+23 | — | 7 patents Insect-based recombinant protein biomanufacturing and engineered insect production of target compounds | 1 job opening · 1 launch |
| 29 | Profound Medical Developer of image guided prostate ablation system for cancer treatment 80Patents top 25%Funding top 31%Innovation top 33%Tech top 34% All 12 signals ▾Patentstop 25% Fundingtop 31% Innovationtop 33% Techtop 34% Moattop 35% Growthtop 36% Newstop 39% Markettop 40% Fin. healthtop 41% Globaltop 44% AItop 45% Partnerstop 45% Patents: 171 patents matched (strict assignee match) · 60 filings since 2022 vs 85 in 2017-21 Funding: Raised $12.9M across 11 rounds · 11 rounds over 18 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 80/100 | $13M | 5 mo ago | 131 | — | WordPressMySQLPHP+27 | 19 signals ▼24% Earnings · Announcements · Funding | 171 patents Patents concentrated in health & consumer products | — |
| 30 | Bionxt Developer of drug formulations and delivery systems for various diseases 37News top 36%Funding top 38%Partners top 40%Patents top 46% All 11 signals ▾Newstop 36% Fundingtop 38% Partnerstop 40% Patentstop 46% Growthtop 47% Talenttop 49% Moatbottom 49% Innovationbottom 46% Techbottom 43% Marketbottom 39% Globalbottom 38% News: 9 BI events in 12 mo (of 28 tracked, 7 types) · -36% YoY Funding: Raised $12.6M across 11 rounds · 11 rounds over 4 yrs (2.8/yr) rank vs industry peers · Fliar Intelligence Index 37/100 | $13M | 15 mo ago | 25 | Hugh Rogers CEO | WordPressMySQLPHP+20 | 9 signals ▼36% Funding · Leadership · Contracts | 7 patents Novel psilocin prodrugs and enteric drug delivery formulations for pharmaceutical applications. | 1 partnership |
| 31 | Kane Biotech Developer of therapeutic solutions to prevent and remove biofilms 45Product top 14%Funding top 32%Patents top 32%Moat top 35% All 11 signals ▾Producttop 14% Fundingtop 32% Patentstop 32% Moattop 35% Innovationtop 40% Techtop 44% Growthtop 50% Talentbottom 49% Newsbottom 47% Globalbottom 42% Marketbottom 35% Product: 4 distinct product lines · Company stage: Public Funding: Raised $12.4M across 9 rounds · 9 rounds over 17 yrs (0.5/yr) rank vs industry peers · Fliar Intelligence Index 45/100 | $12M | 0 mo ago | 25 | Mark Townsend CEO | WordPressMySQLPHP+20 | 4 signals ▼73% Regulatory · Funding · Earnings | 105 patents Topical antimicrobial and anti‑acne pharmaceutical formulations, especially spray gels and dispersin‑based liquids. | — |
| 32 | Devonian Developer of drugs for inflammatory disease and dermatology 19Funding top 38%News top 45%Growth top 48%Global bottom 25% All 5 signals ▾Fundingtop 38% Newstop 45% Growthtop 48% Globalbottom 25% Marketbottom 23% Funding: Raised $11.5M across 7 rounds · 7 rounds over 8 yrs (0.9/yr) News: 6 BI events in 12 mo (of 71 tracked, 8 types) · -25% YoY rank vs industry peers · Fliar Intelligence Index 19/100 | $12M | 10 mo ago | 7 | — | — | 6 signals ▼25% Earnings · Announcements | — | — |
| 33 | Intrepid Labs Developer of drug formulation science to accelerate the development of therapeutics 35Market bottom 49%Funding bottom 49%Talent bottom 49%Global bottom 45% All 4 signals ▾Marketbottom 49% Fundingbottom 49% Talentbottom 49% Globalbottom 45% Funding: Raised $11.0M across 2 rounds · 2 rounds over 3 yrs (0.7/yr) rank vs industry peers · Fliar Intelligence Index 35/100 | $11M | 13 mo ago | — | Christine Allen Co-Founder and CEO | — | — | — | — |
| 34 | Syantra Health Developer of a blood test device to detect breast cancer 53Talent top 23%AI top 30%Growth top 35%Funding top 39% All 8 signals ▾Talenttop 23% AItop 30% Growthtop 35% Fundingtop 39% Moattop 48% Techbottom 40% Globalbottom 36% Marketbottom 29% Talent: 6 named leaders on record · 6 C-suite/founder profiles curated AI: Classified as an AI company · Product described with: artificial intelligence rank vs industry peers · Fliar Intelligence Index 53/100 | $10M | 3 mo ago | 15 | Kenneth Fuh Co-Founder | WebflowTypekitMicrosoft 365+7 | — | — | — |
| 35 | Cardiol Therapeutics Developer of anti-inflammatory therapies for heart disease 53News top 24%Growth top 25%Patents top 31%Moat top 32% All 11 signals ▾Newstop 24% Growthtop 25% Patentstop 31% Moattop 32% Innovationtop 34% Fundingtop 37% Talentbottom 49% Techbottom 41% Globalbottom 36% Partnersbottom 35% Marketbottom 33% News: 16 BI events in 12 mo (of 39 tracked, 6 types) · +129% YoY Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 53/100 | $9M | 8 mo ago | 17 | David Elsley President & CEO/Founder | WordPressApple iCloud MailMicrosoft 365+19 | 16 signals ▲129% Funding · Earnings · Contracts | 55 patents Cannabinoid-based cardiovascular therapies and polymeric drug‑delivery formulations for heart disease | 1 award |
| 36 | Psyence Developer of psychedelic therapeutics for mental health disorders 45News top 26%Growth top 36%Funding top 40%Global top 41% All 7 signals ▾Newstop 26% Growthtop 36% Fundingtop 40% Globaltop 41% Talenttop 49% Marketbottom 43% Techbottom 36% News: 10 BI events in 12 mo (of 25 tracked, 10 types) · +25% YoY Growth: Web rank 10,000,000 → 50,000,000 YoY · 3 acquisition/expansion moves in 24 mo rank vs industry peers · Fliar Intelligence Index 45/100 | $9M | 12 mo ago | — | Alan Friedman Co-Founder | WordPressMySQLPHP+22 | 10 signals ▲25% Board · M&A · Leadership | — | — |
| 37 | Providence Therapeutics Developer of mRNA-based therapeutics for cancer and covid-19 treatment 55Patents top 24%Moat top 32%Innovation top 35%Growth top 35% All 11 signals ▾Patentstop 24% Moattop 32% Innovationtop 35% Growthtop 35% Talenttop 38% Fundingtop 43% Marketbottom 49% Newsbottom 45% Globalbottom 43% Partnersbottom 35% Techbottom 29% Patents: 54 patents matched (strict assignee match) · 54 filings since 2022 vs 0 in 2017-21 Moat: Editorial + unicorn rating 7/10 · IP moat: 54 patents rank vs industry peers · Fliar Intelligence Index 55/100 | $9M | 13 mo ago | 68 | Eric Marcusson Co-Founder | JoomlaPHPThree.js+15 | — | 54 patents Lipid nanoparticle platforms for nucleic acid vaccine delivery and therapeutic formulations | 1 launch |
| 38 | Rakovina Therapeutics Developer of precision medicine to kill cancer cells 27Funding top 37%Patents top 40%Tech top 46%Growth top 47% All 9 signals ▾Fundingtop 37% Patentstop 40% Techtop 46% Growthtop 47% Newstop 48% Moatbottom 49% Innovationbottom 48% Globalbottom 35% Marketbottom 18% Funding: Raised $7.9M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) Patents: 9 patents matched (strict assignee match) · 8 filings since 2022 vs 1 in 2017-21 rank vs industry peers · Fliar Intelligence Index 27/100 | $8M | 13 mo ago | 6 | — | WordPressMySQLPHP+30 | 6 signals ▼33% Board · Earnings | 9 patents Dual PARP‑HDAC inhibitor therapeutics for DNA‑repair and epigenetic cancer treatment | — |
| 39 | Conexeu Sciences Developer of products for skin restoration and wound care 42Talent top 45%Funding top 47%Global bottom 25% All 3 signals ▾Talenttop 45% Fundingtop 47% Globalbottom 25% Talent: 2 named leaders on record Funding: Raised $6.9M across 5 rounds · 5 rounds over 1 yrs (5.0/yr) rank vs industry peers · Fliar Intelligence Index 42/100 | $7M | 3 mo ago | — | Ryan Hartwell Co-Founder & CEO | — | — | — | 1 launch · 1 expansion |
| 40 | Eli Provider of AI-base smart devices for women to monitor reproductive health 72Innovation top 25%Growth top 25%News top 25%Tech top 31% All 11 signals ▾Innovationtop 25% Growthtop 25% Newstop 25% Techtop 31% Talenttop 38% Fundingtop 40% Moattop 44% AItop 45% Producttop 46% Globalbottom 39% Marketbottom 31% Innovation: 4 new-product events in 24 mo · Deep-tech classification: Tech Hardware Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 72/100 | $7M | 12 mo ago | 19 | Marina Rivas Co-Founder & CEO | Cart FunctionalityShopifyShop Pay+28 | 4 signals ▲300% New product | — | — |
| 41 | Telo Genomics Developer of non-invasive prognostic and diagnostic applications that improve disease treatment 37Moat top 31%News top 38%Talent top 39%Partners top 40% All 11 signals ▾Moattop 31% Newstop 38% Talenttop 39% Partnerstop 40% Patentstop 43% Fundingtop 44% AItop 45% Growthtop 48% Innovationbottom 48% Globalbottom 33% Marketbottom 24% Moat: Editorial + unicorn rating 6/10 · IP moat: 9 patents News: 9 BI events in 12 mo (of 37 tracked, 6 types) · -25% YoY rank vs industry peers · Fliar Intelligence Index 37/100 | $5M | 3 mo ago | 6 | Sherif Louis CEO | — | 9 signals ▼25% Leadership · Funding · Contracts | 9 patents Diagnostic assays for smoldering multiple myeloma using nucleic‑acid biomarkers | — |
| 42 | Molecular You Developer of personalized multi-omic digital health platform 53Talent top 28%Innovation top 31%Patents top 31%Moat top 32% All 9 signals ▾Talenttop 28% Innovationtop 31% Patentstop 31% Moattop 32% Techtop 37% Fundingtop 47% Productbottom 48% Globalbottom 36% Marketbottom 33% Talent: Analyst team rating 4/5 Innovation: 24 patents (top 39% of patent-holders) · 19 filings since 2022 vs 5 in 2017-21 rank vs industry peers · Fliar Intelligence Index 53/100 | $5M | 9 mo ago | 28 | — | WordPressApple iCloud MailGoogle Workspace+28 | — | 24 patents Molecular diagnostics and personalized therapeutics for pancreatic cancer, Alzheimer's, autism. | 1 partnership |
| 43 | ViewsML AI-powered platform for drug development and companion diagnostics 21AI top 45%Funding top 46%Talent bottom 49%Global bottom 36% All 5 signals ▾AItop 45% Fundingtop 46% Talentbottom 49% Globalbottom 36% Marketbottom 21% AI: Product described with: ai-powered Funding: Raised $3.6M across 1 rounds · 1 rounds over 2 yrs (0.5/yr) rank vs industry peers · Fliar Intelligence Index 21/100 | $4M | 1 mo ago | 8 | Kenneth To CEO | — | — | — | 1 award |
| 44 | MyndTec Developer of functional electrical stimulation therapy for upper limb paralysis 11Funding top 34%Moat top 38%Talent bottom 45%Global bottom 40% All 7 signals ▾Fundingtop 34% Moattop 38% Talentbottom 45% Globalbottom 40% Patentsbottom 38% Marketbottom 24% Innovationbottom 19% Funding: Raised $3.2M across 13 rounds · 13 rounds over 15 yrs (0.9/yr) Moat: Editorial + unicorn rating 4/10 · IP moat: 17 patents rank vs industry peers · Fliar Intelligence Index 11/100 | $3M | 4 mo ago | 11 | Milos Popovic Co-founder and Director | — | — | 17 patents Implantable neurostimulation devices with wireless telemetry for functional electrical therapy | — |
| 45 | Esphera SynBio Developer of cancer and immunoregulatory treatments using synthetic biology 45Talent top 28%Funding top 45%Global bottom 33% All 3 signals ▾Talenttop 28% Fundingtop 45% Globalbottom 33% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated Funding: Raised $2.4M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 45/100 | $2M | 1 mo ago | — | John Bell Co-Founder | — | — | — | — |
| 46 | Onco-Innovations Developer of therapeutics for cancer treatment 35Funding top 39%Tech top 41%Growth top 45%Talent bottom 49% All 6 signals ▾Fundingtop 39% Techtop 41% Growthtop 45% Talentbottom 49% Marketbottom 31% Globalbottom 25% Funding: Raised $1.9M across 3 rounds · 3 rounds over 1 yrs (3.0/yr) Tech: 26 technologies across 4/8 capability areas · Cloud: Cloudflare rank vs industry peers · Fliar Intelligence Index 35/100 | $2M | 4 mo ago | — | Thomas O Shaughnessy CEO | WordPressMySQLPHP+17 | — | — | 2 partnerships |
| 47 | Andira Digital pharmacotherapeutic platform for providers 21Funding top 50%Talent bottom 49%Market bottom 37%Global bottom 29% All 4 signals ▾Fundingtop 50% Talentbottom 49% Marketbottom 37% Globalbottom 29% Funding: Raised $1.4M across 5 rounds · 5 rounds over 4 yrs (1.2/yr) Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 21/100 | $1M | 3 mo ago | — | Dana Lambert Chief Executive Officer | — | — | — | — |
| 48 | Nanalysis Corp. Manufactures of benchtop NMR spectrometers 74Patents top 22%News top 24%Growth top 25%Innovation top 29% All 10 signals ▾Patentstop 22% Newstop 24% Growthtop 25% Innovationtop 29% Moattop 38% Markettop 39% Partnerstop 40% Fundingtop 46% Techtop 46% Globalbottom 49% Patents: 80 patents matched (strict assignee match) · 39 filings since 2022 vs 17 in 2017-21 News: 15 BI events in 12 mo (of 96 tracked, 9 types) · +114% YoY rank vs industry peers · Fliar Intelligence Index 74/100 | $1M | 5 mo ago | 107 | — | Cart FunctionalitySquarespace CommerceSquarespace+21 | 15 signals ▲114% Earnings · Funding · Announcements | 80 patents Magnetic resonance hardware: magnet pole pieces, structures, and data acquisition systems. | — |
| 49 | Lobe Sciences Developer of small-molecule-based therapeutic solutions for the treatment of neurological disorders 50Growth top 15%News top 25%Moat top 32%Patents top 35% All 10 signals ▾Growthtop 15% Newstop 25% Moattop 32% Patentstop 35% Innovationtop 41% Talenttop 44% Fundingtop 47% Techbottom 46% Globalbottom 33% Marketbottom 25% Growth: Fresh capital in last 24 mo News: 8 BI events in 12 mo (of 14 tracked, 3 types) · +700% YoY rank vs industry peers · Fliar Intelligence Index 50/100 | $942K | 1 mo ago | — | Tom Baird CEO | WixSentryBootstrap+10 | 8 signals ▲700% Earnings · Leadership · Funding | 25 patents Stable psilocin salt formulations for psychedelic drug development and therapeutic use. | — |
| 50 | StokedBio Developer of therapeutics based on AI technology 45Talent top 28%AI top 45%Funding top 46%Market bottom 37% All 5 signals ▾Talenttop 28% AItop 45% Fundingtop 46% Marketbottom 37% Globalbottom 29% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated AI: Product described with: ai-based rank vs industry peers · Fliar Intelligence Index 45/100 | $366K | 1 mo ago | — | Chris Sinclair Co-Founder | — | — | — | — |
Top 12 Life Sciences companies in Canada
#1
Series B · Vancouver, British Columbia · founded 2009$111.4Mraised▾
Series B · Vancouver, British Columbia · founded 2009
Developer of a neurostimulation-based pacer for diaphragm strength. It provides lungpacer system that uses a minimally invasive, transvascular nerve stimulation technology to activate the diaphragm. Its electrodes are intravenously inserted into the lungs to rhythmically activate the diaphragm through neurostimulation to restore negative pressure ventilation. The pacing therapy is used to prevent or reverse diaphragm muscle-disuse atrophy and maintain diaphragmatic endurance.
Fliar Intelligence Index™ 50how this company ranks against its industry peers
Funding
top 23%Innovation
top 27%Moat
top 31%Product
top 35%Tech
top 43%Talent
bottom 49%Funding: Raised $111M across 8 rounds · 8 rounds over 13 yrs (0.6/yr) · Last round Series B (Apr 2026)
Innovation: 3 product lines · Deep-tech classification: Tech Hardware
Moat: Editorial + unicorn rating 8/10 · Soonicorn · 9 curated direct competitors tracked
Audience (LinkedIn): 4k LinkedIn followers
Activity (LinkedIn): 3 product launches announced in 12 mo
Funding rounds
- Apr 2026Series B$12M
- Mar 2025Series B$10M
- Apr 2022Series B$20M
- Jan 2021Grant (prize money)$5.4M
Founders & team
Investors
Canadian Institutes of Health Research, Military Health, KCK MedTech, Keiretsu Capital, Valiance Asset Management, New Enterprise Associates
Tech stack
Apache Http ServerApple Icloud MailCloudflareCloudflare Bot ManagementCookieyesCore-Js
#2
Public · Toronto, Ontario · founded 2004 · 7 employees$247.3Mraised▾
Public · Toronto, Ontario · founded 2004 · 7 employees
ProMIS Neurosciences discovers and develops precision therapeutics and companion diagnostics for early detection and effective treatment of neurodegenerative diseases, in particular, Alzheimer’s disease (AD) and amyotrophic lateral sclerosis (ALS). The company utilizes its computational discovery platform, ProMIS, to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. It owns the exclusive rights to the Genus patent relating to misfolded SOD1 in ALS, and currently has a preclinical monoclonal antibody therapeutic directed against this target.
Fliar Intelligence Index™ 37how this company ranks against its industry peers
Funding
top 10%Patents
top 38%Moat
top 38%Talent
top 38%News
top 42%Innovation
top 47%Funding: Raised $247M across 37 rounds · 37 rounds over 20 yrs (1.9/yr) · Last round Post IPO (Jan 2026)
Patents: 78 patents matched (strict assignee match) · 29 filings since 2022 vs 39 in 2017-21 · Latest publication 2026
Moat: Editorial + unicorn rating 5/10 · IP moat: 78 patents · 10 curated direct competitors tracked
Audience (LinkedIn): 3k LinkedIn followers · 15 engagements/post (2.1× cohort median)
Funding rounds
- Jan 2026Post IPO$175M
- Jul 2025Post IPO$9.2M
- Sep 2023Post IPO$14.9M
- Oct 2022Post IPO$7.5M
Founders & team
Investors
The Kraft Group, Nosterra, Ally Bridge Group, Janus Henderson Investors, Deep Track Capital, Great Point Partners
Tech stack
Apache Http ServerBootstrapFancyboxGodaddyGoogle AnalyticsHcaptcha
#3
Series B · Montreal, Quebec · founded 2021 · 33 employees$65Mraised▾
Series B · Montreal, Quebec · founded 2021 · 33 employees
Developer of therapeutics for the treatment of rare diseases. It offers an in-silico platform that enables the design of small molecules that stabilizes misfolded proteins to treat rare diseases. It offers computational drug discovery engine called Revenir which captures the biophysical changes caused by mutations in proteins. It examines surface features and numerous biophysical descriptors of both the mutated and wild-type proteins. It offers a lead candidate CGX-926 for obesity.
Fliar Intelligence Index™ 50how this company ranks against its industry peers
AI
top 20%Funding
top 24%Moat
top 31%Talent
top 38%Market
bottom 38%Global
bottom 38%AI: Classified as an AI company
Funding: Raised $65.0M across 4 rounds · 4 rounds over 4 yrs (1.0/yr) · Last round Series B (Mar 2026)
Moat: Editorial + unicorn rating 8/10 · Soonicorn · 10 curated direct competitors tracked
Audience (LinkedIn): 7k LinkedIn followers
Hiring (LinkedIn): 1 hiring post in 12 mo (public) · hiring: Senior Scientist in Computational Chemistry
Activity (LinkedIn): 1 partnerships (incl. ONO PHARMACEUTICAL CO., LTD.) announced in 12 mo
Funding rounds
- Mar 2026Series B$39.5M
- Sep 2025Series B$32M
- Mar 2023Series A$15M
- Feb 2022Series A$50M
Founders & team
Investors
Amplitude, Fonds de solidarite FTQ, Lumira Ventures, Invest Quebec, Orbimed, Driehaus
Tech stack
BootstrapCore-JsGodaddyGoogle Font ApiGsapIsotope
#4
Public · Winnipeg, Manitoba · founded 2001 · 25 employees$12.4Mraised▾
Public · Winnipeg, Manitoba · founded 2001 · 25 employees
Developer of therapeutic solutions to prevent and remove biofilms. Its products include ALEDEX, an antimicrobial composition with applications in anti-infective medical device coatings, animal care, and dairy, and food processing industries. DispersinB, an antibiofilm enzyme that inhibits and disperses microbial biofilms, with applications in wound care, medical devices, oral care, and animal healthcare; StrixNB, a drinking water additive for oral care and KBI Antibacterial Disinfectant.
Fliar Intelligence Index™ 45how this company ranks against its industry peers
Product
top 14%Funding
top 32%Patents
top 32%Moat
top 35%Innovation
top 40%Tech
top 44%Product: 4 distinct product lines · Company stage: Public
Funding: Raised $12.4M across 9 rounds · 9 rounds over 17 yrs (0.5/yr) · Last round Post IPO (May 2026)
Patents: 105 patents matched (strict assignee match) · 17 filings since 2022 vs 30 in 2017-21 · Latest publication 2025
Audience (LinkedIn): 6k LinkedIn followers
Activity (LinkedIn): 1 partnerships (incl. Marathon Medical (SDVOSB)) announced in 12 mo
Funding rounds
- Dec 2025Post IPO$508K
- May 2025Post IPO$868.2K
- Jan 2025Post IPO$1.2M
- Jun 2020Grant (prize money)—
Founders & team
Investors
MTEC, Canadian Space Agency, National Research Council Canada, Genesys Venture
Tech stack
AddtoanyCdnjsCloudflareCloudflare Bot ManagementCore-JsFacebook Pixel
#5
Series D · Markham, Ontario · founded 2013 · 32 employees$29.9Mraised▾
Series D · Markham, Ontario · founded 2013 · 32 employees
Exact Imaging has developed a micro-ultrasound based imaging device. The ExactVu system operates at 29MHz waves for higher resolution and is used for imaging prostate cancer and biopsies. The product has an integrated disposable needle biopsy apparatus for visualization and targeting of suspicious small regions. in real-time
Fliar Intelligence Index™ 45how this company ranks against its industry peers
Funding
top 28%Moat
top 32%Growth
top 35%Patents
top 46%Talent
bottom 49%Innovation
bottom 47%Funding: Raised $29.9M across 5 rounds · 5 rounds over 13 yrs (0.4/yr) · Last round Series D (Feb 2026)
Moat: Editorial + unicorn rating 7/10 · IP moat: 45 patents · 9 curated direct competitors tracked
Growth: Fresh capital in last 24 mo
Audience (LinkedIn): 4k LinkedIn followers
Funding rounds
- Feb 2026Series D$10M
- Aug 2019Series C$244.4K
- Feb 2019Series C$7.6M
- Jan 2017Series C$16.1M
Founders & team
Investors
iGan Partners, Veddis App, MaRS IAF, Lumira Ventures, Vesalius Biocapital Partners, PMV
Tech stack
Adobe Experience Platform LaunchApache Http ServerBootstrapCallrailCloudflareCloudflare Bot Management
#6
Late Stage · St. Paul, Alberta · founded 1997 · 94 employees$67Mraised▾
Late Stage · St. Paul, Alberta · founded 1997 · 94 employees
Developer of minimally invasive spinal surgery devices. The company develops surgical techniques, implants, and instruments that conserve spinal bone, nerve, and muscle tissues during orthopedic surgeries. The company offers deployable grafting, pedicular fixation, interbody fusion, retractor, liquid tissue matrix, amniotic wound covering, spinal fixation, allograft, and facet fixation systems. The OptiMesh Deployable Grafting System works by allowing implants to be inserted empty and then deployed to their full size, once in position.
Fliar Intelligence Index™ 57how this company ranks against its industry peers
Funding
top 25%Tech
top 32%Moat
top 39%Growth
top 45%Market
bottom 49%Talent
bottom 49%Funding: Raised $67.0M across 12 rounds · 12 rounds over 24 yrs (0.5/yr) · Last round Unattributed (Nov 2025)
Tech: 33 technologies across 4/8 capability areas · Cloud: Cloudflare · Security: Cloudflare Bot Management, Http/3
Moat: Editorial + unicorn rating 7/10 · 9 curated direct competitors tracked
Audience (LinkedIn): 12k LinkedIn followers — 2.8% of this cohort's audience
Activity (LinkedIn): 2 product launches announced in 12 mo
Funding rounds
- Nov 2025Unattributed$8.8M
- Jul 2024Unattributed$25M
- May 2023Unattributed$5M
- Sep 2021Venture Debt$15M
Founders & team
Investors
Affinity Capital Management, Oak Ridge Financial, Hermed Capital, Horizon, SV Health Investors, 1315 Capital
Tech stack
Animate.CssAstraBeaver BuilderCloudflareCloudflare Bot ManagementCore-Js
#7
Public · Toronto, Ontario · founded 2002 · 50 employees$229.7Mraised▾
Public · Toronto, Ontario · founded 2002 · 50 employees
Provider of psychedelic therapeutics for psychiatric disorders. The product pipeline includes CYB003 a deuterated psilocin for the adjunctive treatment of major depressive disorderCYB004 deuterated dimethyltryptamine compound targeting generalized anxiety disorder and CYB005 aphenethylamine derivative treating neuroinflammation.
Fliar Intelligence Index™ 55how this company ranks against its industry peers
Funding
top 15%Tech
top 42%Talent
top 45%Moat
top 48%Market
bottom 47%Global
bottom 37%Funding: Raised $230M across 6 rounds · 6 rounds over 6 yrs (1.0/yr) · Last round Post IPO (Jun 2025)
Tech: 34 technologies across 4/8 capability areas · Cloud: Cloudflare · Devops: Nginx
Talent: 2 named leaders on record · 1 C-suite/founder profile curated
Audience (LinkedIn): 31k LinkedIn followers — 7.2% of this cohort's audience
Funding rounds
- Jun 2025Post IPO$50M
- Mar 2024Post IPO$150M
- Mar 2022Post IPO$317.1K
- Feb 2021Post IPO—
Founders & team
Investors
Deep Track Capital, Hightrailcapital, Noetic Psychedelic Fund, JLS Fund, Innovating Capital, The Conscious Fund
#8
Series D · Halifax, Nova Scotia · founded 2012 · 1 employees$79.3Mraised▾
Series D · Halifax, Nova Scotia · founded 2012 · 1 employees
Developer of imageable embolic medical devices targeting benign and malignant hypervascular tumors. It offers Eye90 microspheres which are Y‑90 radioembolization microspheres designed for liver tumor therapy, combining tumor treatment with advanced CT imaging visibility for precise dosimetry and visualization. It also offer Easi-Vue embolic microsphere which is an imageable bland embolization product allowing direct visualization at the target site.
Fliar Intelligence Index™ 48how this company ranks against its industry peers
Funding
top 24%Moat
top 32%Growth
top 35%Patents
top 36%Talent
top 38%Innovation
top 39%Funding: Raised $79.3M across 7 rounds · 7 rounds over 14 yrs (0.5/yr) · Last round Series D (Oct 2025)
Moat: Editorial + unicorn rating 7/10 · IP moat: 43 patents · 9 curated direct competitors tracked
Growth: Fresh capital in last 24 mo
Audience (LinkedIn): 6k LinkedIn followers
Activity (LinkedIn): 1 partnerships · 1 expansions (incl. University of Missouri Research Reactor (MURR)) announced in 12 mo
Funding rounds
- Oct 2025Series D$35M
- Apr 2025Series C$26.1M
- Dec 2022Series C$30M
- Sep 2022Series B$18.1M
Founders & team
Investors
Invest Nova Scotia, F-Prime Capital, Varian Medical Systems, Sante, Eight Roads Ventures, Atlantic Canada Opportunities Agency
Tech stack
CloudflareCloudflare Bot ManagementDiviGoogle AnalyticsGoogle Font ApiJquery
#9
Public · Mississauga, Ontario · founded 1999 · 16 employees$21.3Mraised▾
Public · Mississauga, Ontario · founded 1999 · 16 employees
Developer of skin analysis and assessment systems. The company has developed a non-invasive device called SIAscopy technology which utilizes light to view beneath moles and lesions. It includes software that creates real-time images for doctors and dermatologists for evaluating moles and lesions.
Fliar Intelligence Index™ 32how this company ranks against its industry peers
Funding
top 36%Moat
top 38%Tech
top 39%Growth
bottom 47%Patents
bottom 45%Innovation
bottom 44%Funding: Raised $21.3M across 21 rounds · 21 rounds over 10 yrs (2.1/yr) · Last round Post IPO (Feb 2026)
Moat: Editorial + unicorn rating 5/10 · IP moat: 15 patents
Tech: 27 technologies across 4/8 capability areas · Cloud: Cloudflare · Security: Cloudflare Bot Management, Hsts
Audience (LinkedIn): 1k LinkedIn followers
Activity (LinkedIn): 3 product launches announced in 12 mo
Funding rounds
- Feb 2026Post IPO$2M
- Jul 2025Post IPO$387.2K
- Apr 2025Post IPO$671K
- Feb 2025Post IPO$1M
Investors
Agoracom
Tech stack
AngularCart FunctionalityCloudflareCloudflare Bot ManagementCore-JsGodaddy
#10
Series C · Burnaby, British Columbia · founded 2007 · 230 employees$221.4Mraised▾
Series C · Burnaby, British Columbia · founded 2007 · 230 employees
Kardium is developing the Globe mapping and ablation system. It's an investigational medical device, used in the diagnosis and treatment of atrial fibrillation. It provides mapping, stimulation, and RF ablation of cardiac tissue.
Fliar Intelligence Index™ 78how this company ranks against its industry peers
Funding
top 20%Patents
top 25%Product
top 25%Moat
top 26%Innovation
top 27%Talent
top 28%Funding: Raised $221M across 5 rounds · 5 rounds over 16 yrs (0.3/yr) · Last round Series C (Jul 2025)
Patents: 446 patents matched (strict assignee match) · 131 filings since 2022 vs 180 in 2017-21 · Latest publication 2026
Product: 6 distinct product lines · Company stage: Series C
Audience (LinkedIn): 25k LinkedIn followers — 5.9% of this cohort's audience · 152 engagements/post (21.3× cohort median)
Activity (LinkedIn): 1 awards announced in 12 mo
Funding rounds
- Jul 2025Series C$250M
- Jun 2024Series B$104M
- Dec 2020Series B$116.3M
- Feb 2019Series A—
Founders & team
Investors
T. Rowe Price, Fidelity Investments, Durable Capital Partners, Janus Henderson Investors, Qatar Investment Authority, Piper Sandler
Tech stack
Backbone.JsCloudflareCloudflare Bot ManagementCloudflare Browser InsightsCookie NoticeCore-Js
#11
Public · Toronto, Ontario · founded 2007 · 76 employees$27.7Mraised▾
Public · Toronto, Ontario · founded 2007 · 76 employees
A catheter-based ultrasound system for cardiac imaging. The company has developed, Foresight ICE System, a catheter-based ultrasound system capable of providing both 2D and 3D ultrasound images of cardiac anatomy around the circumference of the catheter's tip.
Fliar Intelligence Index™ 48how this company ranks against its industry peers
Funding
top 24%Growth
top 38%News
top 38%Partners
top 40%Moat
top 48%Talent
bottom 49%Funding: Raised $27.7M across 5 rounds · 5 rounds over 7 yrs (0.7/yr) · Last round Post IPO (Jan 2026)
Growth: 2 acquisition/expansion moves in 24 mo · Fresh capital in last 24 mo
News: 14 BI events in 12 mo (of 41 tracked, 11 types) · -18% YoY · 3 high-value events (IPO/M&A/funding/contracts) in 12 mo
Audience (LinkedIn): 9k LinkedIn followers — 2.1% of this cohort's audience
Activity (LinkedIn): 1 product launches · 2 awards announced in 12 mo
Funding rounds
- Jan 2026Post IPO$700K
- Apr 2025Post IPO$15.5M
- Oct 2024Series B$7.7M
- Dec 2021Series B$20M
Founders & team
Investors
FedDev Ontario, Titan Medical, MaRS Discovery District, CPOINT Capital, Tivona Capital, Ontario Brain Institute
Tech stack
GodaddyGoogle CloudGoogle Cloud CdnGoogle Font ApiHttp/3Open Graph
#12
Series A · Montreal, Montreal · founded 2018 · 9 employees$50Mraised▾
Series A · Montreal, Montreal · founded 2018 · 9 employees
Developer of an engineered liver for the treatment of liver diseases. The company's technology ReLiver is an engineered liver tissue that is used to develop an implantable device for acute-on-chronic liver failure, an extracorporeal bio-artificial liver device, and an in vitro assay for next-generation drug discovery.
Fliar Intelligence Index™ 45how this company ranks against its industry peers
Talent
top 28%Funding
top 31%Growth
top 35%Moat
top 42%Tech
top 49%Global
bottom 36%Talent: Analyst team rating 4/5
Funding: Raised $50.0M across 2 rounds · 2 rounds over 5 yrs (0.4/yr) · Last round Series A (Dec 2025)
Growth: Fresh capital in last 24 mo
Audience (LinkedIn): 5k LinkedIn followers
Activity (LinkedIn): 2 awards · 1 expansions announced in 12 mo
Funding rounds
- Dec 2025Series A$10M
- Feb 2024Series A$40M
- Jul 2021Seed—
Investors
CQDM, Invest Quebec, CDP Venture Capital, Genson Capital
Tech stack
BootstrapEnvoyGodaddyGoogle CloudGoogle Cloud CdnGsap
Funding & investor landscape
$36.2Btotal disclosed funding
527companies funded
1,814disclosed rounds
8rounds last 90 days
Most active investors
Notable founders
Doug Evans
President & CEO · Lungpacer
Neil Cashman
Co-Founder · ProMIS Neurosciences
Elliot Goldstein Md
President & CEO · ProMIS Neurosciences
Michael Goldsmith
Co-Founder · Congruence Therapeutics
Clarissa Desjardins
Co-Founder & CEO · Congruence Therapeutics
Mark Townsend
CEO · Kane Biotech
Randy Aucoin
President & CEO · Exact Imaging
Brian Snider
Chief Executive Officer · Spineology
Aaron Bartlone
COO · Cybin
Sarah Hamilton
Director Financial Operations & Strategic Operations · Cybin
Sharon Kehoe
Co-Founder · ABK Biomedical
Michael Mangano
CEO & President · ABK Biomedical
Prism market signals · Canada · country-scoped Prism corpus, 188,258 docs
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
RESEARCH SIGNALS · Canada
How research on Biotechnology is moving in Canada
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 990 Canada-affiliated papers.
research sentiment over time
200820162026
enthusiastic · positive · guarded tone
Tone is overwhelmingly optimistic and intensifying — the enthusiastic (strongly-positive) share moved 39% → 44% across 2008–2026.
top research entities
- Ministry of Agriculture118
- Ministry of Education70
- University of Toronto61
- McGill University60
- Agriculture and Agri-Food Canada58
leading researchers
Davoud Torkamaneh · Maxime de Ronne · Vincent Lefebvre · Sylvie Deslauriers · Théo Devèze · Bernard R. Glick · Rotimi E. Aluko · Warren C. W. Chan
▲
Breakthroughs267 · 27%
▼ 31%→27% share
▼0.9× share momentum0 median citations82% since 2021mostly empirical
Gene-focused breakthrough research surged from 3 to 32 papers, with antibody and immune system topics newly emerging at 12 and 8 papers respectively.
rising sub-themes (early→recent)
- Gene3→32
- Mutant2→13
- Genome2→12
- Transcription factor2→11
- Transcription (linguistics)1→9
Newly emergingAntibody 0→12 · Immune system 0→8 · Mutation 0→7
Landmark In situ click chemistry generation of cyclooxygenase-2 inhibitors · 7,514 cites
◆
Advancements374 · 38%
▲ 31%→40% share
▲1.3× share momentum0 median citations86% since 2021mostly empirical
Microbiome and transcriptome advancements newly emerged at 15 papers each as Gene research scaled from 2 to 40 papers.
rising sub-themes (early→recent)
- Gene2→40
- Fermentation1→12
- Antimicrobial1→9
- Population1→9
- Agriculture1→8
Newly emergingMicrobiome 0→15 · Transcriptome 0→15 · Metagenomics 0→10
Landmark Lignin Valorization: Improving Lignin Processing in the Biorefinery · 3,958 cites
▼
Concerns164 · 17%
▼ 22%→14% share
▼0.6× share momentum0 median citations71% since 2021mostly reviews
Antibiotic resistance and agriculture concerns intensified to 10 papers each while the segment's overall field-share cooled from 22% to 14%.
rising sub-themes (early→recent)
- Agriculture3→10
- Antibiotic resistance3→10
- Antimicrobial1→6
- Human health2→7
- Microbiome2→6
Newly emergingContext (archaeology) 0→8 · Resistance (ecology) 0→6 · Gene 0→6
Landmark The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate · 8,812 cites
RESEARCH HOTSPOTS · Canada
Where biotechnology is researched across Canada
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Montreal99 · +0.45
Edmonton/Calgary71 · +0.39
Toronto63 · +0.49
Vancouver61 · +0.40
Ottawa/Kingston34 · +0.40
Waterloo/Hamilton31 · +0.41
PATENT SIGNAL · Canada
Who's filing biotechnology patents in Canada
Canada biotechnology patent filing is accelerating — 18,553 filings from 8,000 assignees (2016–2025), led by UNIV British Columbia, UNIV Health Network, NAT RES Council Canada; annual filings 1716→1734.
18,553 filings8,000 assigneespeak 2082/yr2016–2025
filing momentum (YoY 2016–2025)
top patent filers
- UNIV British Columbia1570
- UNIV Health Network1208
- NAT RES Council Canada900
- UNIV Alberta753
- CA NAT Research Council699
- Medicago680
- UNIV Saskatchewan598
- Zymeworks594
Common questions
How many Life Sciences companies are there in Canada?
Radar tracks 1567 indexable Life Sciences companies headquartered in Canada that meet our profile-completeness bar.
What is the total funding raised by Life Sciences companies in Canada?
The Life Sciences companies in Canada on this list have raised a combined $36.2B in disclosed equity funding across 527 funded companies.
Which is the highest-funded Life Sciences company in Canada?
Bausch Health is the highest-funded Life Sciences company in Canada, with $25.7B in disclosed equity funding.
How many Life Sciences companies in Canada are funded?
527 of the 1567 Life Sciences companies in Canada on this list have disclosed at least one equity funding round.
How many Life Sciences unicorns are there in Canada?
None of the Life Sciences companies in Canada on this list currently has a disclosed valuation of $1B or more.
Who are the top investors in Canada Life Sciences companies?
The most active investors in Canada Life Sciences companies on this list include BDC, Ontario Centre of Innovation, Ontario Brain Institute, UTEST, MaRS Discovery District.
Rohit KhannaTrends & Stories
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.